首页> 美国卫生研究院文献>Therapeutic Advances in Medical Oncology >Eribulin mesylate use as third-line therapy in patients withmetastatic breast cancer (VESPRY): a prospective multicentre observationalstudy

【2h】

Eribulin mesylate use as third-line therapy in patients withmetastatic breast cancer (VESPRY): a prospective multicentre observationalstudy

机译：甲磺酸依瑞布林作为三线治疗转移性乳腺癌（VESPRY）：前瞻性多中心观察性研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

In real-world practice, eribulin mesylate provides significant survivalbenefit, with a manageable safety profile in heavily pretreated patientswith metastatic breast cancer (MBC).

机译：在实际操作中，甲磺酸艾力布林可提供显着的存活率大量预处理的患者具有可控的安全性转移性乳腺癌（MBC）。

著录项

期刊名称 Therapeutic Advances in Medical Oncology
作者
Vincenzo Adamo; Giuseppina Rosaria Rita Ricciardi; Dario Giuffrida; Giuseppa Scandurra; Antonio Russo; Livio Blasi; Pietro Spadaro; Carmelo Iacono; Hector J. Soto Parra; Antonino Savarino; Francesco Ferraú; Filippo Zerilli; Francesco Verderame; Alfredo Butera; Carlo Santangelo; Veronica Franchina; Michele Caruso;
展开▼
作者单位

展开▼
年(卷),期 2019(11),-1
年度 2019
页码 -1
总页数 7
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词
eribulin; metastatic breast cancer; multicentre; prospective; real world; third line;

机译：eribulin;转移性乳腺癌;多中心;前瞻性;现实世界;第三线;

相似文献

外文文献
中文文献
专利

1. 来自一项艾日布林联合吉西他滨对比紫杉醇联合吉西他滨作为HER2阴性转移性乳腺癌的一线化疗的II期、多中心、随机试验的包含神经病变相关量表的生活质量结果:韩国癌症研究组试验(KCSG BR13-11) [J] . Ji-Yeon Kim, Young-Hyuck Im, Tae-Yong Kim, 癌症（英文版） . 2019,第008期
2. Eribulin mesylate use as third-line therapy in patients with metastatic breast cancer (VESPRY): a prospective, multicentre, observational study [J] . Vincenzo Adamo, Giuseppina Rosaria Rita Ricciardi, Dario Giuffrida, Therapeutic advances in medical oncology. . 2019,第12期

机译：Eribulin甲磺酸盐用作转移性乳腺癌患者的第三线疗法（Vespry）：一种预期，多期，观察研究
3. Use of Eribulin mesylate as second-line therapy in elderly patients with HER/2 negative metastatic breast cancer (MBC): efficacy, tolerability and Quality of Life [J] . R. De Luca, M. Alù, G. Genova, European review for medical and pharmacological sciences. . 2020,第24期

机译：使用Eribulin甲磺酸盐作为二线治疗的老年患者（MBC）：疗效，耐受性和生活质量
4. Eribulin Mesylate as Third or Subsequent Line Chemotherapy for Elderly Patients with Locally Recurrent or Metastatic Breast Cancer: A Multicentric Observational Study of GIOGer (Italian Group of Geriatric Oncology)-ERIBE [J] . Leo Silvana, Arnoldi Ermenegildo, Repetto Lazzaro, The oncologist . 2019,第6期

机译：Eribulin甲磺酸盐作为第三或后续的局部复发性或转移性乳腺癌患者的化疗：Gioger的多中心观察研究（意大利老年肿瘤学群） - 人
5. Clinical Outcome of Breast and Ovarian Cancer Patients Treated after High-Dose Chemotherapy and Autologous Stem Cell Rescue with Theratope (STn-KLH) Cancer Vaccine: Theratope (STn-KLH) Cancer Vaccine following Autologous Transplant [C] . Leona A. Holmberg, Katherine A. Guthrie, Brenda M. Sandmaier Chemical glycobiology . -1

机译：大剂量化学疗法和自体干细胞拯救治疗的Theratope（STn-KLH）癌症疫苗治疗的乳腺癌和卵巢癌患者的临床结果：自体移植后的Theratope（STn-KLH）癌症疫苗
6. The Effects of Adjuvant Chemotherapy on Brain Function in Breast Cancer Patients and a Cancer-Chemotherapy Rodent Model. [D] . Barr, Alicia Thomas. 2014

机译：辅助化疗对乳腺癌患者脑功能的影响和癌症化学疗法的啮齿动物模型。
7. Prospective Analysis of Patients with Metastatic Breast Cancer receiving Eribulin Mesylate as Second or More Lines of Chemotherapy: An Indian Experience [O] . BJ Srinivasa, Bhanu Prakash Lalkota, Girish Badarke, 2018

机译：甲磺酸依瑞布林作为第二或更多化疗方案的转移性乳腺癌患者的前瞻性分析：印度的经验
8. PCN280 Analysis of Eribulin Mesylate Utilzation in Patients with Metastatic Breast Cancer (Mbc) by Line of Therapy and Associated Changes Over Time [O] . Feinberg BA, Drenning J, Garofalo DF, 2015

机译：转移性乳腺癌（Mbc）患者的治疗方式及其随时间变化的PCN280分析甲磺酸依瑞布林的使用

Eribulin mesylate use as third-line therapy in patients withmetastatic breast cancer (VESPRY): a prospective multicentre observationalstudy

摘要

著录项

相似文献

相关主题

期刊订阅